News | December 19, 2025
Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The state-of-the-art facility is expected to be commissioned over the next three years
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Subscribe To Our Newsletter & Stay Updated
